Phosphodiesterase isoenzymes in equine platelets and their influence on platelet adhesion

American Journal of Veterinary Research

Volumn 68, Issue 12, 2007, Pages 1354-1360

  Dunkel, Bettina ^a   Rickards, Karen J ^b,c   Page, Clive P ^b   Cunningham, Fiona M ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c THE DONKEY SANCTUARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; SPLEEN EXONUCLEASE;

ANIMAL CELL; ARTICLE; CALORIMETRY; CELL ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; HORSE; MALE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN TARGETING; RADIOIMMUNOASSAY; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION;

ANIMALS; BLOOD PLATELETS; CELL ADHESION; CELLS, CULTURED; DOSE FRACTIONATION; HORSES; ISOENZYMES; MALE; PHOSPHORIC DIESTER HYDROLASES; PLATELET AGGREGATION INHIBITORS;

EQUIDAE;

EID: 37249052352     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.12.1354     Document Type: Article

References (42)

1. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003;1:1897-1905.
2. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001;62:1153-1161.
3. Ablett, JM, Fairbairn SM, Page CP et al. Influence of antigen challenge on platelet responsiveness in horses with chronic obstructive pulmonary disease. Equine Vet J 1997;29:382-386.
4. Weiss DJ, Evanson OA, McClenahan D, et al. Evaluation of platelet activation and platelet-neutrophil aggregates in ponies with alimentary laminitis. Am J Vet Res 1997;58:1376-1380.
5. Weiss DJ, Trent AM, Johnston G. Prothrombotic events in the prodromal stages of acute laminitis in horses. Am J Vet Res 1995;56:986-991.
6. Weiss DJ, Geor RJ, Johnston G, et al. Microvascular thrombosis associated with onset of acute laminitis in ponies. Am J Vet Res 1994;55:606-612.
7. Evans RJ. Blood platelets and their role in the genesis and sequelae of intestinal ischemia. Equine Vet J Suppl 1992;13:31-37.
8. Barton MH, Morris DD, Norton N, et al. Hemostatic and fibrinolytic indices in neonatal foals with presumed septicemia. J Vet Intern Med 1998;12:26-35.
9. Dallap BL, Dolente B, Boston RC. Coagulation profiles in 27 horses with large colon volvulus. J Vet Emerg Crit Care 2003;13:215-225.
10. Dolente BA, Wilkins PA, Boston RC. Clinicopathologic evidence of disseminated intravascular coagulation in horses with acute colitis. J Am Vet Med Assoc 2002;220:1034-1038.
11. Dolente BA, Beech J, Lindborg S, et al. Evaluation of risk factors for development of catheter-associated jugular thrombophlebitis in horses: 50 cases (1993-1998). J Am Vet Med Assoc 2005;227:1134-1141.
12. Brianceau P, Divers TJ. Acute thrombosis of limb arteries in horses with sepsis: five cases (1988-1998). Equine Vet J 2001;33:105-109.
13. Pellegrini-Masini A, Dolente BA, Habecker PL, et al. Myonecrosis and cutaneous infarction associated with Salmonella serovar Infantum infection in a horse. J Am Vet Med Assoc 2004;225:699, 722-725.
14. Forrest LJ, Cooley AJ, Darien BJ. Digital arterial thrombosis in a septicemic foal. J Vet Intem Med 1999;13:382-385.
15. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol 2006;147(suppl 1):S252-S257.
16. Castro A, Jerez MJ, Gil C, et al. Cyclic nucleoticle phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphochesterase inhibitors. Med Res Rev 2005;25:229-244.
17. Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004;16(suppl 1):S11-S14.
18. Kittleson MD. The efficacy and safety of milrinone for treating heart failure in dogs. Vet Clin North Am Small Anim Pract 1991;21:905-918.
19. Lombard CW, Jons O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006;42:249-261.
20. Leguillette R, Desevaux C, Lavoie JP. Effects of pentoxifylline on pulmonary function and results of cytologic examination of bronchoalveolar lavage fluid in horses with recurrent airway obstruction. Am J Vet Res 2002;63:459-463.
21. Barton MH, Moore JN, Norton N. Effects of pentoxifylline infusion on response of horses to in vivo challenge exposure with endotoxin. Am J Vet Res 1997;58:1300-1307.
22. Ingle-Fehr JE, Baxter GM. The effect of oral isoxsuprine and pentoxifylline on digital and laminar blood flow in healthy horses. Vet Surg 1999;28:154-160.
23. Cesarini C, Hamilton E, Picandet V, et al. Theophylline does not potentiate the effects of a low dose of dexamethasone in horses with recurrent airway obstruction. Equine Vet J 2006;38:570-573.
24. Rickards KJ, Page CP, Lees P, et al. Phosphodiesterase activity in neutrophils from horses with chronic obstructive pulmonary disease. Vet Immunol Immunopathol 2000;76:319-330.
25. Rickards KJ, Page CP, Hamblin AS, et al. Biochemical and functional assessment of equine lymphocyte phosphodiesterases and protein kinase C. Vet Immunol immunopathol 2004;98:153-165.
26. Rickards KJ, Andrews MJ, Waterworth TH, et al. Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation. J Vet Pharmacol Ther 2003;26:277-282.
27. Eriksson AC, Whiss PA. Measurement of adhesion of human platelets in plasma to protein surfaces in microplates. J Pharmacol Toxicol Methods 2005;52:356-365.
28. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
29. Foster AP, McCabe PJ, Sanjar S, et al. Agonist-induced adherence of equine eosinophils to fibronectin. Vet Immunol Immunopathol 1997;56:205-220.
30. Beavo JA. Cyclic nudeotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725-748.
31. Ito M, Nishikawa M, Fujioka M, et al. Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cell Signal 1996;8:575-581.
32. Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001;13:282-290.
33. Cooper N, Teixeira MM, Warneck J, et al. A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. Br J Pharmacol 1999;126:1863-1871.
34. Whalin ME, Scammell JG, Strada SJ, et al. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells. Mol Pharmacol 1991;39:711-717.
35. Torphy TJ, Stadel JM, Burman M, et al. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram. binding in yeast. J Biol Chem 1992;267:1798-1804.
36. Nicholson CD, Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes-their potential utility in the therapy of asthma. Pulm Pharmacol 1994;7:1-17.
37. DiFazio LT, Stratoulias C, Greco RS, et al. Multiple platelet surface receptors mediate platelet adhesion to surfaces coated with plasma proteins. J Surg Res 1994;57:133-137.
38. Nakamura T, Ariyoshi H, Kambayashi J, et al. Signal transduction system in epinephrine stimulated platelets; comparison between epinephrine sensitive and insensitive platelets. Thromb Res 1997;85:83-93.
39. Rickards KJ, Page CP, Cunningham FM. Allergen challenge alters lymphocyte phosphodiesterase activity in horses with heaves. Pulm Pharmacol Ther 2004;17:163-172.
40. Chan SC, Hanifin JM. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med 1993;121:44-51.
41. Landells LJ, Spina D, Souness JE, et al. A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects. Pulm Pharmacol Ther 2000;13:231-239.
42. Sly MK, Eberhart RC, Prager MD. Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors. Shock 1997;8:115-118.